CAPRICOR THERAPEUTICS, INC.

corporate_fare Company Profile

CAPRICOR THERAPEUTICS, INC.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed CAPR - Latest Insights

Filing Type

Date Range

CAPR

Apr 10, 2026, 4:31 PM EDT

Filing Type: DEF 14A

Importance Score:

7

Capricor Therapeutics Schedules Annual Meeting, Re-proposes Officer Exculpation Amendment, and Details Executive Compensation

Sentiment: Negative

View Wiseek Article

CAPR

Mar 31, 2026, 5:24 PM EDT

Filing Type: PRE 14A

Importance Score:

7

Capricor Therapeutics Seeks Shareholder Approval for Officer Exculpation Amendment After Prior Failure

Sentiment: Negative

View Wiseek Article

CAPR

Mar 17, 2026, 5:00 PM EDT

Filing Type: 10-K

Importance Score:

8

Capricor Therapeutics Reports Strong Phase 3 Data for Deramiocel, Secures $265M in Financing, and Confirms August 2026 PDUFA Date

Sentiment: Positive

View Wiseek Article

CAPR

Mar 12, 2026, 4:01 PM EDT

Filing Type: 8-K

Importance Score:

8

Capricor Therapeutics Reports Q4/FY25 Results, Secures Cash Runway, and Advances Deramiocel BLA with August 2026 PDUFA Date

Sentiment: Positive

View Wiseek Article

CAPR

Mar 12, 2026, 9:00 AM EDT

Source: GlobeNewswire

Importance Score:

9

New HOPE-3 Data: Deramiocel Significantly Improves Duchenne Muscular Dystrophy Patient Function

Sentiment: Positive

View Wiseek Article

CAPR

Mar 10, 2026, 9:25 AM EDT

Source: GlobeNewswire

Importance Score:

8

FDA Lifts CRL for Capricor's Deramiocel, Sets August 2026 PDUFA Date for DMD Therapy

Sentiment: Positive

View Wiseek Article